Adaptive Biotechnologies vs Arvinas
Adaptive Biotechnologies and Arvinas are similar in size: $277m and $263m of revenue in their latest fiscal years. Adaptive Biotechnologies grew faster (54.8% against -0.3%). Adaptive Biotechnologies kept more of each dollar of sales as profit: a net margin of -21.5% against -30.8%. Arvinas carries less debt relative to equity (0.1% against 60.0%).
| Latest fiscal year | Adaptive BiotechnologiesADPT, 2025 | ArvinasARVN, 2025 |
|---|---|---|
| Revenue | $277m | $263m |
| Revenue growth | 54.8% | -0.3% |
| Net income | −$59.5m | −$80.8m |
| Operating margin | -20.6% | -45.1% |
| Net margin | -21.5% | -30.8% |
| Return on equity | -28.2% | -16.2% |
| Free cash flow | −$48.9m | −$276m |
| Cash | $70.5m | $143m |
| Total debt | $131m | $600,000 |
| Debt to equity | 60.0% | 0.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $91.9m |
| Employees | 624 | 246 |
| Market value | $4.10bn | $462m |
| Price vs our value range | — | — |
| Moat score | 24 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 168 sales | 1 buys, 23 sales |